Acadia Pharma (ACAD) Tops Q3 EPS by 9c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $26.74 -2.02%
Revenue Growth %: +19.3%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: +19.3%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.53), $0.09 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.03 million.
GUIDANCE:
Acadia Pharma sees FY2017 revenue of $124-127 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- LEEF Brands appoints Hirsh Jain to board as independent director
- Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
